-1.6%
ORLY vs MRNA
+945.0%
-946.6%
-18.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.6% | +13.1% | -10.5% | +2.6% |
| 7D | +2.1% | +20.6% | -18.5% | +2.0% |
| 30D | +10.1% | +27.1% | -17.1% | +9.9% |
| 3M | +0.6% | +353.4% | -352.8% | -0.2% |
| 6M | -1.7% | +446.3% | -448.0% | -3.8% |
| YTD | +1.2% | +776.2% | -774.9% | -0.4% |
| 1Y | -1.6% | +987.9% | -989.5% | -3.8% |
| All | -1.6% | +945.0% | -946.6% | -3.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling